Did you know that by the end of 2015 there will be 850,000 people in the UK with Alzheimer’s or some other form of dementia? Quite a staggering statistic isn’t it? When coupled with the fact that it’s the sixth leading cause of death, and it’s something that can’t be cured, prevented or slowed down, we begin to gain a little more understanding of the impact conditions such as Alzheimer’s are having and going to have on the western world.
These statistics make it all the more important for scientists to find new screening methods and to develop new forms of clinical care for dementia and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This month is ‘Alzheimer’s and Brain Awareness Month’ in the United States, and as part of this, one of the country’s leading neuroscientists, James Galvin, has presented some of the cutting edge research he’s currently undertaking in an effort to combat these diseases.
An international expert on Lewy Body Disease
As a leading international expert on ‘Lewy Body disease’, the second most common degenerative disease¸ Galvin has been at the forefront of research to develop new dementia screening tools, and has carried out many cross cultural screening methods for dementia. It’s estimated that over 100,000 people in the UK suffer from Lewy Body disease experiencing the simultaneous loss of cognitive function, mobility and behaviour. As part of his research, Galvin has combined and developed biomarkers in an attempt to characterise and distinguish between LBD and other neurodegenerative diseases.
Millions of dollars generated in funding
Galvin, a professor of clinical biomedical science, has been involved in a number of research projects to develop screening tools for dementia, and has generated funding amounting to millions of dollars from various sources, including the Alzheimer Association and the Michael J. Fox Foundation. He and his team are currently working on ways to detect the disease as early as possible and improve the accuracy of diagnosis, so that the correct treatments can be given from the start.